Name: 글로벌 시장 동향
SKU: MD4917
Availability: InStock

보고서 요약(국문)

경피적 삼첨판막 중재술(TTVI) 시장 규모는 2022년 YY백만 달러였으며, 예측 기간(2023-2030) 동안 높은 연평균 성장률(CAGR)을 기록하며 2030년에는 YY백만 달러에 이를 것으로 예상됩니다. 삼첨판막 역류증은 우심실과 우심방 사이의 판막이 제대로 닫히지 않아 혈액이 우심방으로 역류하는 심장 판막 질환의 일종입니다. 만성 삼첨판막 역류증 환자는 전통적으로 약물 치료를 받아 왔지만, 이로 인해 판막륜 확장 및 말기 우심실 심부전이 발생할 수 있습니다. 8 최근 삼첨판막 중재술(TTVI)이 중증 삼첨판막 역류증(TR) 치료의 대안으로 떠오르고 있습니다.
경피적 삼첨판 중재술 시장 동향
삼첨판 역류(TR) 치료를 위해 개발된 새로운 기술들이 시장 성장을 견인할 것으로 예상됩니다.
삼첨판 역류(TR)는 삶의 질과 장기 생존율에 부정적인 영향을 미치므로, 이러한 영향을 완화할 수 있는 치료법에 대한 관심이 높아지고 있습니다. 과거에는 TR에 대한 유일한 치료법이 수술이었지만, 이는 다른 질환을 동반한 고령 환자에게 상당한 이환율과 사망률을 유발하는 경우가 많았습니다. 치료 선택의 폭이 좁아짐에 따라 경피적 삼첨판 중재술(TTVI)이 빠르게 발전해 왔습니다. 다양한 기법이 연구되고 있으며, 초기 데이터에 따르면 TTVI는 임상 결과를 개선하는 것으로 나타났습니다. 현재 TTVI는 판막 가장자리 봉합술, 판륜 축소술, 스페이서 삽입술, 대정맥 판막 이식술, 경피적 삼첨판 치환술 등 다양한 방법을 기반으로 합니다. 예를 들어, 많은 삼첨판 역류 질환은 판륜 확장을 동반하며, 특히 삼첨판 역류 초기 단계에서는 판륜 성형술이 주요 수술 기법으로 사용됩니다. 반면, 경피적 판륜 축소술은 삼첨판륜을 축소하고, 판막 접합 간격을 닫고, 판막 소엽의 근접성을 회복함으로써 외과적 판륜 성형술을 모방하는 것을 목표로 합니다. 따라서 이러한 이유로 시장은 예측 기간 동안 성장할 것으로 예상됩니다.
하지만 경피적 삼첨판 중재술(TTVI)과 관련된 위험은 시장 성장을 저해할 것으로 예상됩니다.
삼첨판 복구 및 교체 수술의 위험은 환자의 건강 상태, 치료 방법, 그리고 의료진의 숙련도에 따라 다릅니다. 합병증 위험을 줄이기 위해서는 삼첨판 수술 경험이 풍부하고 숙련된 의료진이 있는 의료기관에서 수술을 시행해야 합니다. 삼첨판막 복구 및 교체 수술은 출혈, 혈전, 인공판막의 기능 장애, 심장 박동 장애, 감염, 뇌졸중, 심지어 사망과 같은 위험을 수반합니다.
경피적 삼첨판막 중재술(TAVR) 시장 동향: COVID-19 영향 분석
COVID-19 팬데믹은 의료 시스템과 시장에 상당한 영향을 미쳤습니다. 봉쇄 조치와 팬데믹 자체는 의료 운영에 광범위한 변화를 가져왔습니다. 특히 중환자 치료 분야에서 많은 국가와 의료 시스템이 심각한 서비스 부담을 겪었으며, 이러한 요구를 충족하기 위해 자원 재배치가 필요했습니다. COVID-19는 사람들이 의료 서비스를 이용하는 방식 또한 변화시켰습니다. COVID-19 팬데믹 기간 동안 TAVR 및 SAVR 시술 건수가 급격히 감소했습니다. 2020년 3월부터 6월까지 이러한 시술 감소로 인해 중증 대동맥 협착증 환자 약 2,294명이 TAVR 또는 수술적 치료를 받지 못한 것으로 추산됩니다.

더욱이, 봉쇄 조치, 여행 금지 및 기타 요인으로 인해 COVID-19 팬데믹은 여러 국가에서 삼첨판막 복구 및 교체 기기의 임상 및 확증 시험, 파이프라인 주요 단계, 규제 승인 및 허가에 영향을 미쳤습니다. 따라서 COVID-19는 선별 검사, 의료 협회 승인 및 임상 시험 활동의 중단 또는 연기로 인해 모든 단계에서 임상 및 수술 관행에 심각한 영향을 미쳤습니다.
경피적 삼첨판막 중재술 시장 역학 부문 분석
삼첨판막 복구(TVr) 부문은 경피적 삼첨판막 중재술(TTVI) 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
삼첨판막 복구(TVr) 부문은 2020년에 시장을 주도할 것으로 예상됩니다. 대부분의 삼첨판막 질환은 기계적 질환으로 약물 치료만으로는 성공적으로 관리할 수 없습니다. 증상 및 심부전과 같은 합병증의 위험으로 인해 결국 수술이 필요하게 됩니다. 손상된 삼첨판을 복구할지 여부는 삼첨판 질환의 심각도, 환자의 나이, 전반적인 건강 상태 등 여러 요인에 따라 결정됩니다. 심장 판막 복구는 감염 위험이 낮기 때문에 일반적으로 첫 번째 선택입니다. 판막 복구는 심장 기능을 보존하고 개선하며, 장기간 혈액 희석제 복용 필요성을 줄일 수 있습니다. 따라서 삼첨판 복구(TVr)에 대한 수요가 증가했으며, 이로 인해 해당 시장 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
경피적 삼첨판 중재술 시장 동향 지역 분석
북미 지역은 전 세계 경피적 삼첨판 중재술(TTVI) 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
2020년 북미는 가장 높은 매출 점유율을 기록했습니다. 삼첨판 질환의 유병률 증가, 경피적 삼첨판 중재술(TA) 기기에 대한 치료 선호도 증가, 그리고 기술 발전으로 인한 TA 적용 확대, 시장 참여자들의 신제품 출시, 그리고 용이한 보험 적용은 향후 예측 기간 동안 시장 성장을 촉진할 것으로 예상되는 요인들입니다. 예를 들어, 삼첨판 역류(TR)의 유병률은 증가하고 있으며, 미국에서는 약 160만 명의 환자가 중증 TR을 앓고 있는 것으로 추산됩니다. 그럼에도 불구하고, 매년 삼첨판 수술을 받는 환자는 8,000명 미만입니다. 더욱이, 최근 연구에 따르면 승모판 수술 시 TA를 병행하는 것이 승모판 수술만 받은 환자에 비해 2년 후 1차 평가변수 발생 위험을 낮추는 것으로 나타났습니다.
또한, 일리노이주 애벗 파크에 위치한 애벗 연구소는 자사의 Triclip 경피적 삼첨판 복구 시스템에 대한 CE 인증을 획득했습니다. 제조사에 따르면, 이 장치는 삼첨판 역류(TR)에 대한 비수술적 치료법이며, 상용화된 최초의 최소 침습 클립 기반 삼첨판 복구 장치입니다. 트라이클립(Triclip)은 다리의 대퇴정맥을 통해 심장에 공급되는 장치로, 삼첨판 판막의 일부를 클립으로 고정하여 혈액 역류를 줄입니다. 따라서 위의 내용을 바탕으로 북미 지역이 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
경피적 삼첨판 중재술 시장 동향 및 경쟁 환경
경피적 삼첨판 중재술(TTVI) 시장의 주요 업체로는 Edwards Lifesciences, Abbott Laboratories, Medtronic, Venus MedTech, Navigate Cardiac Structures, Inc., CroíValve 및 Cardiovalve가 있습니다.

애보트 연구소:
개요:
애보트 연구소(Abbott)는 진단 기기, 당뇨병 관리, 시력 기술, 혈관 제품, 영양 및 동물 건강 제품을 개발, 제조 및 판매합니다. 이 회사는 충족되지 않은 의료 요구를 해결하기 위해 혁신적인 의료 기기를 제공합니다. 진단 부문을 통해 약물 검사 제품 및 솔루션을 제공합니다. 자궁경부암 진단 의료 기기 업계의 글로벌 리더인 애보트 혈관(Abbott Vascular)은 관상동맥 질환 치료를 위한 혁신적이고 최소 침습적이며 비용 효율적인 제품을 제공합니다. 이 회사는 약물 방출 스텐트, 베어메탈 스텐트, 관상동맥 가이드 와이어, 풍선 확장 카테터, 가이드 카테터 및 액세서리를 포함한 광범위한 포트폴리오를 제공합니다. 애보트 연구소는 전 세계 150개국 이상에서 사업을 운영하고 있습니다.
제품 포트폴리오:
트리클립 경피적 삼첨판 복구술(TriClip Transcatheter Tricuspid Valve Repair): 삼첨판 역류(TR)를 지속적으로 감소시키고 임상적으로 유의미한 결과를 제공하며 안전성이 입증되었습니다. 이 제품은 우심장에 특화된 검증된 클립 기반 플랫폼을 기반으로 제작되었습니다.

보고서 요약(영어 원문)

Transcatheter tricuspid valve intervention (TTVI) market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a high CAGR during the forecast period (2023-2030).Tricuspid valve regurgitation is a type of heart valve disease in which the valve between the two right heart chambers (right ventricle and right atrium) doesn't close properly. As a result, blood leaks backward into the upper right chamber (right atrium). Patients with chronic TR have traditionally been treated medically, which has resulted in annular dilatation and end-stage right ventricular (RV) heart failure. 8 tricuspid valve intervention (TTVI) has recently emerged as an alternative for treating severe tricuspid regurgitation (TR).
Transcatheter Tricuspid Valve Intervention Market Dynamics
Novel Techniques developed for treating tricuspid regurgitation (TR) are expected to drive market growth.
Tricuspid regurgitation (TR) negatively influences both quality of life and long-term survival, sparking interest in treatment ways to counteract these effects. Historically, the only treatment option for TR was surgery, which is often accompanied by considerable morbidity and mortality in older patients with other comorbidities. Due to a lack of therapeutic choices, transcatheter tricuspid valve intervention (TTVI) has rapidly evolved. A wide range of techniques is studied, and early data suggests that TTVI improves clinical outcomes. Today, TTVI is based on various methods, including edge-to-edge repair, annular reduction, spacers, caval valve implantation, and transcatheter tricuspid valve replacement. For instance, Many TR diseases involve annular dilatation, and many surgical methods, particularly in the early phases of TR, focus on annuloplasty as a primary technique. Percutaneous annular reduction techniques, on the other hand, aim to emulate surgical annuloplasty by shrinking the tricuspid annulus, closing the coaptation gap, and restoring leaflet approximation. Thus, the market is expected to drive in the forecast period from the above statements.
Risks associated with the Transcatheter Tricuspid Valve Intervention (TTVI) surgery are expected to hamper the market growth.
The risks of tricuspid valve repair and replacement vary based on health, the treatment, and the health care team's skill. To lessen the risk of complications, tricuspid valve surgery should be performed at a medical center with skilled staff who have performed many tricuspid valve surgeries. Bleeding, blood clots, valve malfunction in replacement valves (valve prosthesis), heart rhythm disorders, infection, stroke, or even death are all risks connected with tricuspid valve repair and replacement operations.
Transcatheter Tricuspid Valve Intervention Market Dynamics COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. The lockdown restrictions, as well as the pandemic itself, have caused extensive modifications in healthcare operations. Many countries and healthcare systems, particularly in critical care, have experienced substantial service strain. It has demanded the reorganization of resources to meet those needs. COVID-19 has altered how people connect with health services at the same time. There was a rapid and significant decrease in TAVR and SAVR activity during the COVID-19 pandemic. It is estimated that over the period March to June 2020, this decline in activity accounts for an estimated 2294 patients with severe aortic stenosis left untreated by TAVR or surgical intervention.
Moreover, because of lockdowns, travel boycotts, and other factors, the COVID-19 epidemic has affected clinical and confirmatory trials, pipeline milestones, and regulatory clearances and approvals of tricuspid valve repair and replacement devices in several countries. Thus, COVID-19 has profoundly impacted clinical and surgical practice at every level, with the suspension or postponement of screening, medical association approvals, and clinical trial activities.
Transcatheter Tricuspid Valve Intervention Market Dynamics Segment Analysis
Tricuspid Valve Repair (TVr) segment is expected to hold the largest market share in transcatheter tricuspid valve intervention (TTVI) market
The tricuspid valve repair (TVr) segment is expected to dominate in 2020. Most tricuspid valve disorders are mechanical and cannot be successfully managed with medicine alone. Symptoms and the risk of consequences, such as heart failure, will eventually necessitate surgery. The decision to repair a damaged tricuspid valve depends on many things, including the severity of your tricuspid valve disease, age and overall health of the patient and others. Heart valve repair is usually the first choice because it's associated with a lower risk of infection. Valve repair preserves and improves heart function, and it may reduce the potential need for long-term use of blood-thinning medications. Thus, it has increased the demand for Tricuspid Valve Repair (TVr), due to which the market segment is expected to hold the largest market share in the forecast period.
Transcatheter Tricuspid Valve Intervention Market Dynamics Geographical Analysis
North America region holds the largest market share in the global transcatheter tricuspid valve intervention (TTVI) market
In 2020, North America accounted for the highest revenue share. The increasing prevalence of tricuspid valve diseases, increasing preference for transcatheter tricuspid valve intervention devices for treatment, and technological advancements lead to enhanced Transcatheter Tricuspid Valve Intervention applications, product launches by the market players, and easy availability of reimbursement are some factors that the market is expected to boost in the forecast period. For instance, The prevalence of TR is increasing, with an estimated prevalence of around 1.6 million patients with significant TR in the USA. Nonetheless, fewer than 8,000 patients undergo tricuspid valve surgery per year. Moreover, recent research further showed that the inclusion of TA at the time of mitral valve surgery resulted in a lower risk of a primary-end-point event at 2 years than those who underwent mitral-valve surgery alone.
Additionally, Abbott Laboratories of Abbott Park, Illinois, has acquired CE approval for its Triclip transcatheter tricuspid valve repair system. According to the manufacturer, the device is a non-surgical treatment for tricuspid regurgitation (TR), and it is the first commercially available minimally invasive clip-based tricuspid valve repair device. The Triclip is a device supplied to the heart through the femoral vein in the leg and reduces blood backflow by clipping together a part of the tricuspid valve's leaflets. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Transcatheter Tricuspid Valve Intervention Market Dynamics Competitive Landscape
Major key players in the transcatheter tricuspid valve intervention (TTVI) market are Edwards Lifesciences, Abbott Laboratories, Medtronic, Venus MedTech, Navigate Cardiac Structures, Inc., CroíValve and Cardiovalve.
Abbott Laboratories:
Overview:
Abbott Laboratories (Abbott) develops, manufactures, and markets diagnostic devices, diabetes care, vision technologies, vascular products, and nutrition and animal health products. The company provides innovative medical devices to fulfill unmet healthcare needs. The company provides drug testing products and solutions through its diagnostics segment. Abbott Vascular, a global leader in the Cervical Cancer Diagnostics medical device industry, provides innovative, minimally invasive and cost-effective products to treat coronary artery disease. The company offers an extensive portfolio of drug-eluting stents, bare-metal stents, coronary guide wires, balloon dilatation catheters, and guiding catheters and accessories. Abbott Laboratories operates its business in over 150 countries worldwide.
¬Product Portfolio:
TriClip Transcatheter Tricuspid Valve Repair: It offers a sustained reduction of TR with significant clinical outcomes and proven safety improvement. It is built upon a proven clip-based platform uniquely designed for the right heart.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Intervention Type
3.2. Market Snippet by Disease Type
3.3. Market Snippet by End User
3.4. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Novel Techniques developed for treating tricuspid regurgitation (TR) are expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Risks associated with the Transcatheter Tricuspid Valve Intervention (TTVI) surgery are expected to hamper the market growth.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Supply Chain Analysis
5.2. Pricing Analysis
5.3. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Intervention Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intervention Type
7.1.2. Market Attractiveness Index, By Intervention Type Segment
7.2. Tricuspid Valve Repair (TVr)*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Tricuspid Valve Replacement (TVR)
8. By Disease Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type Segment
8.2. Tricuspid Stenosis (TS)*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Tricuspid Regurgitation (TR)
9. By End-user
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
9.1.2. Market Attractiveness Index, By End user Segment
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Ambulatory Surgical Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intervention Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intervention Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intervention Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intervention Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intervention Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. Edwards Lifesciences*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Abbott Laboratories
12.3. Medtronic
12.4. Venus MedTech
12.5. Navigate Cardiac Structures, Inc.
12.6. CroíValve
12.7. Cardiovalve(*LIST NOT EXHAUSTIVE)
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us

언급된 주요 기업들

Edwards Lifesciences, Abbott Laboratories, Medtronic, Venus MedTech, Navigate Cardiac Structures, Inc., CroíValve

표 목록 (Tables)

List of Tables

Table1 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Intervention Type, 2022, 2026 & 2030 ($ Million)

Table2 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Disease Type, 2022, 2026 & 2030 ($ Million)

Table3 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By End user, 2022, 2026 & 2030 ($ Million)

Table4 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Region, 2022, 2026 & 2030 ($ Million)

Table5 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Intervention Type, 2022, 2026 & 2030 ($ Million)

Table6 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Intervention Type, 2022-2030 ($ Million)

Table7 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Disease Type, 2022, 2026 & 2030 ($ Million)

Table8 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Disease Type, 2022-2030 ($ Million)

Table9 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By End user, 2022, 2026 & 2030 ($ Million)

Table10 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By End user, 2022-2030 ($ Million)

Table11 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Region, 2022, 2026 & 2030 ($ Million)

Table12 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Region, 2022-2030 ($ Million)

Table13 North America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Intervention Type, 2022-2030 ($ Million)

Table14 North America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Disease Type, 2022-2030 ($ Million)

Table15 North America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By End user, 2022-2030 ($ Million)

Table16 North America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Country, 2022-2030 ($ Million)

Table17 South America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Intervention Type, 2022-2030 ($ Million)

Table18 South America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Disease Type, 2022-2030 ($ Million)

Table19 South America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By End user, 2022-2030 ($ Million)

Table20 South America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Country, 2022-2030 ($ Million)

Table21 Europe Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Intervention Type, 2022-2030 ($ Million)

Table22 Europe Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Disease Type, 2022-2030 ($ Million)

Table23 Europe Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By End user, 2022-2030 ($ Million)

Table24 Europe Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Country, 2022-2030 ($ Million)

Table25 Asia-Pacific Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Intervention Type, 2022-2030 ($ Million)

Table26 Asia-Pacific Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Disease Type, 2022-2030 ($ Million)

Table27 Asia-Pacific Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By End user, 2022-2030 ($ Million)

Table28 Asia-Pacific Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Country, 2022-2030 ($ Million)

Table29 Middle East & Africa Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Intervention Type, 2022-2030 ($ Million)

Table30 Middle East & Africa Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By Disease Type, 2022-2030 ($ Million)

Table31 Middle East & Africa Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, By End user, 2022-2030 ($ Million)

Table32 Edwards Lifesciences: Overview

Table33 Edwards Lifesciences: Product Portfolio

Table34 Edwards Lifesciences: Key Developments

Table35 Abbott Laboratories: Overview

Table36 Abbott Laboratories: Product Portfolio

Table37 Abbott Laboratories: Key Developments

Table38 Medtronic: Overview

Table39 Medtronic: Product Portfolio

Table40 Medtronic: Key Developments

Table41 Venus MedTech: Overview

Table42 Venus MedTech: Product Portfolio

Table43 Venus MedTech: Key Developments

Table44 Navigate Cardiac Structures, Inc.: Overview

Table45 Navigate Cardiac Structures, Inc.: Product Portfolio

Table46 Navigate Cardiac Structures, Inc.: Key Developments

Table47 CroíValve: Overview

Table48 CroíValve: Product Portfolio

Table49 CroíValve: Key Developments

Table50 Cardiovalve: Overview

Table51 Cardiovalve: Product Portfolio

Table52 Cardiovalve: Key Developments

그림 목록 (Figures)

List of Figures

Figure1 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Intervention Type, 2022 & 2030 (%)

Figure2 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Disease Type, 2022 & 2030 (%)

Figure3 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By End user, 2022 & 2030 (%)

Figure4 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Region, 2022 & 2030 (%)

Figure5 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure6 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Y-o-Y Growth, By Intervention Type, 2020-2028 (%)

Figure7 Tricuspid Valve Repair (TVr): Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure8 Tricuspid Valve Replacement (TVR): Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure9 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Y-o-Y Growth, By Disease Type, 2020-2028 (%)

Figure10 Tricuspid Stenosis (TS): Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure11 Tricuspid Regurgitation (TR) : Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure12 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Y-o-Y Growth, By End user, 2020-2028 (%)

Figure13 Hospitals: Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure14 Ambulatory Surgical Centers: Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure15 Others: Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure16 Global Transcatheter Tricuspid Valve Intervention (TTVI) Market Y-o-Y Growth, By Region, 2020-2028 (%)

Figure17 North America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure18 North America Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Intervention Type, 2022 & 2030 (%)

Figure19 North America Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Disease Type, 2022 & 2030 (%)

Figure20 North America Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By End user, 2022 & 2030 (%)

Figure21 North America Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Country, 2022 & 2030 (%)

Figure22 South America Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure23 South America Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Intervention Type, 2022 & 2030 (%)

Figure24 South America Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Disease Type, 2022 & 2030 (%)

Figure25 South America Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By End user, 2022 & 2030 (%)

Figure26 South America Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Country, 2022 & 2030 (%)

Figure27 Europe Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure28 Europe Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Intervention Type, 2022 & 2030 (%)

Figure29 Europe Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Disease Type, 2022 & 2030 (%)

Figure30 Europe Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By End user, 2022 & 2030 (%)

Figure31 Europe Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Country, 2022 & 2030 (%)

Figure32 Asia-Pacific Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure33 Asia-Pacific Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Intervention Type, 2022 & 2030 (%)

Figure34 Asia-Pacific Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Disease Type, 2022 & 2030 (%)

Figure35 Asia-Pacific Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By End user, 2022 & 2030 (%)

Figure36 Asia-Pacific Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Country, 2022 & 2030 (%)

Figure37 Middle East & Africa Transcatheter Tricuspid Valve Intervention (TTVI) Market Value, 2022-2030 ($ Million)

Figure38 Middle East & Africa Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Intervention Type, 2022 & 2030 (%)

Figure39 Middle East & Africa Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By Disease Type, 2022 & 2030 (%)

Figure40 Middle East & Africa Transcatheter Tricuspid Valve Intervention (TTVI) Market Share, By End user, 2022 & 2030 (%)

Figure41 Edwards Lifesciences: Financials

Figure42 Abbott Laboratories: Financials

Figure43 Medtronic: Financials

Figure44 Venus MedTech: Financials

Figure45 Navigate Cardiac Structures, Inc.: Financials

Figure46 CroíValve: Financials

Figure47 Cardiovalve: Financials